Evidence-Based Positioning of Sodium-Glucose Co-transporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in the Management of Chronic Kidney Disease with Type 2 Diabetes and Overweight o
6 hours ago
- #type 2 diabetes
- #obesity
- #chronic kidney disease
- SGLT2 inhibitors are consistently favored over GLP-1 receptor agonists for composite kidney outcomes and reducing progression of kidney disease in patients with chronic kidney disease (CKD), type 2 diabetes, and overweight or obesity.
- GLP-1 receptor agonists are suggested as complementary adjunct therapy to SGLT2 inhibitors, which should be considered foundational for kidney protection, metabolic, and cardiovascular benefits.
- The review highlights the lack of head-to-head trials directly comparing SGLT2 inhibitors and GLP-1 receptor agonists, emphasizing the need for more evidence on optimal combination and sequencing.